SV-BR-1-GM

Phase 3Biologic

BBriaCell Therapeutics Corporation

SV-BR-1-GM is one of 41 biologic programs targeting Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerRecruiting

Breast CancerPhase 3

Recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

SV-BR-1-GM

BBriaCell Therapeutics Corporation

Phase 3

2 2

Lexiscan

Astellas

Preclinical

1 3

Voltaren

Novartis

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

Blenoxane

Bristol-Myers Squibb

Preclinical

1 6

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 8

Duragesic-100

CCephalon

Preclinical

2 9

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 10

Spravato

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 3Recruiting

Breast Cancer

NCT06072612

Clinical

Trials by Indication[1]

Breast Cancer2 trials

SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer

Completed·BBriaCell Therapeutics Corporation·Phase 1/2·NCT03066947·24 enrolled

Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Recruiting·BBriaCell Therapeutics Corporation·Phase 3·NCT06072612·404 enrolled

Unspecified1 trial

Combination Study of SV-BR-1-GM With Retifanlimab

Enrolling by invitation·BBriaCell Therapeutics Corporation·Phase 1/2·NCT03328026·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for SV-BR-1-GM. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SV-BR-1-GM compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SV-BR-1-GM. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BriaCell Therapeutics Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: BBriaCell Therapeutics Corporation

SV-BR-1-GM

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Breast Cancer2 trials

Unspecified1 trial

References

Drug Info

Quick Facts

Related News